Antialdosteronics renaissance in the contemporary cardiology
Authors:
M. Štejfa
Published in the journal:
Kardiol Rev Int Med 2005, 7(1): 21-24
Summary
We present an overview on synthesis and effects of aldosterone and their competitive inhibitors spironolactone and eplerenone. We briefly mention the indications, contraindications and adverse effects of the nonspecific inhibitor spironolactone in patients with primary and secondary hyperaldosteronism and its significance in hypertension treatment. Small doses of spironolactone (25 mg daily) in chronic heart failure NYHA II–IV represent a new indication, where the antiproliferative effect on progression of heart failure takes place (RALES study). Eplerenon is a specific inhibitor and presents a minimum of adverse effects. It was successfully tested in patients with hypertensive left ventricular hypertrophy (4E study) and in patients suffering from chronic heart failure (the EPHESUS study).
Keywords:
aldosterone – spironolactone – eplerenone – chronic heart failure – left ventricular hypertrophy – hypertension
Zdroje
1. Biollaz J et al. Antihypertensive therapy with MK421. J Cardiovasc Pharmacol 1982; 4(6): 966–972.
2. Bozkurt B et al. Complications of inappropriate use of spironolactone in heart failure. J Am Coll Cardiol 2003; 41(2): 211–214.
3. Packer M. The neurohumoral hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Card 1992; 20: 248–254.
4. Pitt B et al. The effect of spironolactone on morbidity and mortality in patiens with severe heart failure. N Engl Med J 1999; 341: 709–717.
5. Pitt B et al. The EPHESUS trial: eplerenon in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction: eplerenon post–acute myocardial infarction heart failure efficacy and survival study. Cardiovasc Drug Ther 2001; 15: 79–87.
6. Pitt B et al. Efficacy and safety of eplerenone, enalapril and eplerenone/enalapril combination therapy in pacients with left ventricular hypertrophy. Am J Hypertens 2002; 15: 23.
7. Pitt B et al. Eplerenon post–acute myocardial infarction heart failure efficacy and survival study. N Engl J Med 2003; 348: 1309–1321.
8. Struthers AD. Aldosterone escape dutiny angiotensin–converting enzyme therapy in chronic heart failure. J Cardiac Failure 1996; 2(1): 47–54.
9. Swedberg K et al. Hormones regulating function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82(5): 1730–1736.
10. Weber KT. Aldosterone and spironolactone in heart failure. N Engl Med J 1999; 341: 753–755.
11. Widimský J et al. Improvement of heart failure 2. Cor Vasa 2001; 43: 345–352.
Štítky
Paediatric cardiology Internal medicine Cardiac surgery CardiologyČlánok vyšiel v časopise
Cardiology Review
2005 Číslo 1
Najčítanejšie v tomto čísle
- Trimetazidine in the treatment of angina pectoris and other forms of IHD
- Practical aspects and news in pharmacological treatment of arrhythmias
- Rehabilitation after myocardial infarction
- Antialdosteronics renaissance in the contemporary cardiology